Half-Year 2022 Financial Performance

H1 and H2 Performance Balanced underlying H1 and H2 performance expected H12022 H2 2022 Lonza FY 2022 in-line with guidance Sales growth CER¹ Third-party Sales to former Specialty Ingredients Large customer cancellation fee Sales phasing in Small Molecules Delivery of Small Molecules orders produced in H1 Large customer cancellation not yet fully backfilled Low to mid-teens CER1 sales growth CORE EBITDA margin Growth project profitability Large customer cancellation fee Inflationary pressure 1 Constant Exchange Rate 22024 CORE EBITDA margin Mid-Term Guidance of ~33-35% Phasing of corporate cost items Inflationary pressure Improvement in- line with MTG2 trajectory CORE definition: See appendix 17

View entire presentation